Santa Ana-based Fujifilm Irvine Scientific Inc. announced Mar. 22 it will acquire Shenandoah Biotechnology Inc. of Pennsylvania for an undisclosed amount.
Shenandoah Biotechnology manufacturers recombinant proteins, which have various applications, including cell therapy, gene therapy and regenerative medicine, the company said.
“Fujifilm Irvine Scientific is committed to helping customers bring advanced therapies to market faster, and to use innovation to make therapies more accessible,” Fujifilm Scientific Irvine’s CEO Yutaka Yamaguchi said in a statement. “Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs.”
Fujifilm Irvine Scientific Inc., a subsidiary of Tokyo-based Fujifilm Holdings America Corporation (OTC: FUJIY), creates serum-free, chemically defined cell culture media, reagents, and medical devices for life science research, bioproduction, and cell therapy manufacturing, officials said. The 52-year-old company operates dual manufacturing facilities in California and Japan.
The deal will not only merge all of Shenandoah’s employees, but help Fujifilm reach its sales target of $850 million by 2025, Yamaguchi added.
It’s slated to close later this month.
